MDManoela Dantas

Manoela Dantas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manoela Dantas has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Federated Learning in Anesthesiology: A Privacy-Preserving Approach to Collaborative Predictive Modeling

    by Victor F. A. Almeida, Manoela Dantas, Glaudir Donato, Avneep Aggarwal

  • Ketorolac in Breast Reduction: Balancing Analgesia and Bleeding Risk

    by Victor F. A. Almeida, Glaudir Donato, Manoela Dantas, Eliana F. R. Duraes

    The perioperative use of ketorolac in breast reduction surgery requires careful consideration of both its analgesic benefits and potential bleeding risks. In response to recent correspondence, we highlight that our meta-analysis stratified hematomas by severity, recognizing that even conservatively managed cases may influence patient satisfaction in aesthetic surgery. The current evidence base remains limited by heterogeneity in dosing protocols, timing of administration, and surgical techniques, underscoring the need for randomized controlled trials and patient-level data analyses. Although ketorolac may confer opioid-sparing effects, the clinical significance of this reduction has yet to be clearly established. The potential impact on bleeding risk should be carefully evaluated, particularly in patients with additional predisposing factors. Clinical judgment and individualized assessment remain central to optimizing perioperative analgesia and safety in aesthetic breast surgery. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.


  • Open Access

    Liposomal Bupivacaine in Transversus Abdominis Plane Block for Postoperative Pain Control After Autologous Breast Reconstruction: A Systematic Review and Meta‐Analysis

    by Victor F. A. Almeida, Glaudir Donato, Andressa Alves de Carvalho, Wanessa Alves de Carvalho, Ammar Lakda, Yara Dias, Manoela Dantas, Pedro Danielian, Eliana F. R. Duraes

    Background: Autologous breast reconstruction using abdominally based flaps is common post‐mastectomy, but donor‐site pain often leads to prolonged opioid use. The transversus abdominis plane ( TAP ) block is a common regional anesthesia technique, with bupivacaine as the standard anesthetic. Liposomal bupivacaine ( LB ), a prolonged‐release formulation, aims to extend pain relief and reduce opioid consumption, though its efficacy remains debated. Objective: This systematic review and meta‐analysis compared LB versus plain bupivacaine ( PB ) in TAP blocks for autologous breast reconstruction, focusing on opioid consumption, pain scores, and hospital stay. Methods: A systematic search identified randomized controlled trials and observational studies comparing LB (with or without PB ) to PB in TAP blocks. Data were pooled using a random‐effects model ( I 2 ≥ 25%) or fixed‐effects model ( I 2 < 25%). Results: Six studies (429 patients) met inclusion criteria. LB was associated with significant reduction in opioid consumption on postoperative days ( POD ) 1 ( MD = −4.99 mg; 95% CI : [−8.42; −1.56], p < 0.01, I 2 = 0%) and POD 2 ( MD = −3.35 mg; 95% CI : [−5.74; −0.96], p < 0.01, I 2 = 0%). Pain scores were significantly lower on POD 2 and POD 3. No difference in hospital stay was found ( MD = −0.17; 95% CI : [−0.52; 0.18], p = 0.34, I 2 = 83.1%). Conclusion: LB reduced opioid consumption during the first 48 h postoperatively and modestly improved pain control on POD 2 and POD 3, but did not shorten hospital stay. Further large‐scale RCTs are needed to validate its benefits.


  • Open Access

    Perioperative Ketorolac and Hematoma Following Breast Reduction: A Systematic Review and Meta-analysis

    by Victor F. A. Almeida, Glaudir Donato, Manoela Dantas, Eliana F. R. Duraes

    Background: Ketorolac, a nonsteroidal anti-inflammatory drug, is a promising opioid-sparing option for postoperative pain control. However, its impact on platelet function raises concerns about bleeding risk. Reduction mammaplasty carries a known risk of hematoma, and this study aimed to assess whether perioperative ketorolac increases this risk. Methods: We searched Cochrane Central, Embase, PubMed, and Web of Science databases for studies involving breast reduction patients who did or did not receive perioperative ketorolac. The primary outcome was hematoma formation, with secondary outcomes distinguishing between cases requiring surgery and those managed conservatively. A random-effects model calculated pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was assessed using the I 2 statistic. Results: Seven studies involving 3,418 patients were included—1991 in the ketorolac group and 1427 in the control group. The hematoma incidence was 6.13% in the ketorolac group versus 6.73% in controls. Meta-analysis revealed a significantly increased risk of hematoma in ketorolac users (OR 2.63, 95% CI 1.58–4.37, p < 0.001, I 2 = 37.5%), particularly in cases managed conservatively (OR 2.72, 95% CI 1.37–5.38, p = 0.004, I 2 = 26.3%). Sensitivity analysis reinforced these findings, also demonstrating an association between ketorolac and hematomas requiring reoperation. Conclusion: Perioperative ketorolac is associated with an increased risk of hematoma following breast reduction surgery. While it provides effective opioid-sparing analgesia, its use should be carefully considered, especially in patients with higher bleeding risks. Further randomized trials are needed to refine safety recommendations. Level of Evidence II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266